AZD6094

DRUG3 trials

Sponsors

AstraZeneca, Samsung Medical Center

Conditions

Advanced Gastric AdenocarcinomaPapillary Renal Cell Cancer

Phase 1

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

CompletedNCT02447406

Samsung Medical CenterAdvanced Gastric Adenocarcinoma

Start: 2015-04-30End: 2020-09-20Updated: 2022-06-15

Phase 2

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

CompletedNCT02127710

AstraZenecaPapillary Renal Cell Cancer

Start: 2014-04-30End: 2020-04-20Updated: 2021-04-19

Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

CompletedNCT02447380

Samsung Medical CenterAdvanced Gastric Adenocarcinoma

Start: 2017-07-10End: 2019-02-18Updated: 2019-12-30

Related Papers

Abstract 4541: <i>MET</i> gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor

Cancer Research2018-07-014 citations

A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).

Journal of Clinical Oncology2017-02-2010 citations

cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).

Journal of Clinical Oncology2015-03-016 citations